Tianjin Development (00882.HK): Lisheng Pharmaceutical's attributable net profit for the first three quarters was RMB 78.51 million, a year-on-year decrease of 78.82%.

Zhitong Finance APP News, Tianjin Development (00882.HK) announced the results of Lisheng Pharmaceutical for the nine months ended September 30, 2026, with total operating revenue of RMB 888 million, a year-on-year decrease of 11.84%; net profit attributable to owners of the parent company of RMB 78.51 million, a year-on-year decrease of 78.82%; basic earnings per share of RMB 0.25.